{"title":"Efficacy of minocycline in substance use disorder: A systematic review of preclinical and clinical studies","authors":"Sahar Eshrati , Marjan Nikbakhtzadeh , Reza Arezoomandan , Azin Fattahi","doi":"10.1016/j.pbb.2025.173982","DOIUrl":null,"url":null,"abstract":"<div><div>Addiction is a serious condition that leads to negative changes in the central nervous system. Although there have been significant advancements in medication treatments for substance use disorders (SUDs), it is clear that there is a need to implement these developments in clinical settings to explore new therapeutic approaches for helping individuals with SUDs. Minocycline, a semi-synthetic second-generation tetracycline, possesses neuroprotective and anti-inflammatory properties. Recent studies have shown promising results when using this drug for the treatment of substance misuse. This study aimed to review the pre-clinical and clinical studies assessing the therapeutic efficacy of minocycline on drug-related outcomes, including reward, tolerance, withdrawal, impairments, and toxicity. We conducted a systematic review to assess the effectiveness of minocycline in ameliorating drug-induced outcomes per the PRISMA guidelines. Electronic medical databases Web of Science, PubMed/Medline, Scopus, and Google Scholar were searched from databases from their inception date until December 2023. 56 of the 623 articles met the eligible criteria for analysis. Of the 56 articles reviewed, 51 were conducted on animals, while 5 involved human subjects. Our study indicates that the majority of animal studies have primarily focused on morphine and alcohol, with no research found to date on the effects of cannabis. This review highlights minocycline's potential in addiction treatment through its effects on anti-inflammatory mechanisms, neuroprotection, regulation of synaptic plasticity. Results of this study suggest that although minocycline shows promise in experiments, its effectiveness in humans may be limited by dosage, individual variability, and addiction's complexity. Further clinical studies are required to clarify the optimal dose, duration of administration, and delivery route and focus on identifying specific conditions where it may be most effective.</div></div>","PeriodicalId":19893,"journal":{"name":"Pharmacology Biochemistry and Behavior","volume":"250 ","pages":"Article 173982"},"PeriodicalIF":2.5000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacology Biochemistry and Behavior","FirstCategoryId":"102","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0091305725000292","RegionNum":3,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/22 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"BEHAVIORAL SCIENCES","Score":null,"Total":0}
引用次数: 0
Abstract
Addiction is a serious condition that leads to negative changes in the central nervous system. Although there have been significant advancements in medication treatments for substance use disorders (SUDs), it is clear that there is a need to implement these developments in clinical settings to explore new therapeutic approaches for helping individuals with SUDs. Minocycline, a semi-synthetic second-generation tetracycline, possesses neuroprotective and anti-inflammatory properties. Recent studies have shown promising results when using this drug for the treatment of substance misuse. This study aimed to review the pre-clinical and clinical studies assessing the therapeutic efficacy of minocycline on drug-related outcomes, including reward, tolerance, withdrawal, impairments, and toxicity. We conducted a systematic review to assess the effectiveness of minocycline in ameliorating drug-induced outcomes per the PRISMA guidelines. Electronic medical databases Web of Science, PubMed/Medline, Scopus, and Google Scholar were searched from databases from their inception date until December 2023. 56 of the 623 articles met the eligible criteria for analysis. Of the 56 articles reviewed, 51 were conducted on animals, while 5 involved human subjects. Our study indicates that the majority of animal studies have primarily focused on morphine and alcohol, with no research found to date on the effects of cannabis. This review highlights minocycline's potential in addiction treatment through its effects on anti-inflammatory mechanisms, neuroprotection, regulation of synaptic plasticity. Results of this study suggest that although minocycline shows promise in experiments, its effectiveness in humans may be limited by dosage, individual variability, and addiction's complexity. Further clinical studies are required to clarify the optimal dose, duration of administration, and delivery route and focus on identifying specific conditions where it may be most effective.
上瘾是一种严重的疾病,会导致中枢神经系统的负面变化。尽管药物治疗在物质使用障碍(SUDs)方面取得了重大进展,但很明显,有必要在临床环境中实施这些发展,以探索帮助SUDs患者的新治疗方法。二甲胺四环素是一种半合成的第二代四环素,具有神经保护和抗炎特性。最近的研究表明,当使用这种药物治疗药物滥用时,有希望的结果。本研究旨在回顾评估米诺环素对药物相关结果治疗效果的临床前和临床研究,包括奖励、耐受性、停药、损伤和毒性。我们根据PRISMA指南对米诺环素在改善药物诱导预后方面的有效性进行了系统评价。电子医学数据库Web of Science、PubMed/Medline、Scopus和谷歌Scholar从数据库建立之日起至2023年12月进行检索。623篇文章中有56篇符合分析标准。在被审查的56篇文章中,51篇是在动物身上进行的,5篇是在人类身上进行的。我们的研究表明,大多数动物研究主要集中在吗啡和酒精上,迄今为止还没有发现关于大麻影响的研究。本文综述了米诺环素在抗炎机制、神经保护、调节突触可塑性等方面在成瘾治疗中的潜力。这项研究的结果表明,尽管二甲胺四环素在实验中显示出希望,但其对人类的有效性可能受到剂量、个体差异和成瘾复杂性的限制。需要进一步的临床研究来明确最佳剂量、给药时间和给药途径,并重点确定可能最有效的具体情况。
期刊介绍:
Pharmacology Biochemistry & Behavior publishes original reports in the areas of pharmacology and biochemistry in which the primary emphasis and theoretical context are behavioral. Contributions may involve clinical, preclinical, or basic research. Purely biochemical or toxicology studies will not be published. Papers describing the behavioral effects of novel drugs in models of psychiatric, neurological and cognitive disorders, and central pain must include a positive control unless the paper is on a disease where such a drug is not available yet. Papers focusing on physiological processes (e.g., peripheral pain mechanisms, body temperature regulation, seizure activity) are not accepted as we would like to retain the focus of Pharmacology Biochemistry & Behavior on behavior and its interaction with the biochemistry and neurochemistry of the central nervous system. Papers describing the effects of plant materials are generally not considered, unless the active ingredients are studied, the extraction method is well described, the doses tested are known, and clear and definite experimental evidence on the mechanism of action of the active ingredients is provided.